Public Company News

Canadian Solar's e-STORAGE Launches SolBank 3.0 with Higher Density and Advanced Safety

GUELPH, ON, Dec. 12, 2023 /PRNewswire/ -- Canadian Solar Inc . (the "Company" or "Canadian Solar") (NASDAQ: CSIQ) today announced thate-STORAGE , which is part of the Company's majority-owned subsidiary CSI Solar Co., Ltd. ("CSI Solar"), wil...

2023-12-12 20:00 2888

NaaS Technology and GAC Energy Collaborate on Establishment of a Connected Charging Service Network

BEIJING, Dec. 12, 2023 /PRNewswire/ -- Recently, NaaS, the first U.S. listed EV charging service company inChina (NASDAQ: NAAS), together with its strategic partner Kuaidian, has entered into cooperation with GAC Energy Technology Co., Ltd. (hereinafter referred to as GAC Energy), a subsidiary of...

2023-12-12 18:28 3963

Gravitas Education Holdings, Inc. Announces Expected Timing for the Effective Time of the Merger

BEIJING, Dec. 12, 2023 /PRNewswire/ -- Gravitas Education Holdings, Inc. (the "Company") (NYSE: GEHI) announced that the effective time of the merger between Bright Sunlight Limited, aCayman Islands exempted company and a direct, wholly owned subsidiary of the Company (the "Merger Sub") and Elmtr...

2023-12-12 18:00 3638

Dizal Impresses with Its Differentiated Hematological Oncology Portfolio at 2023 ASH

SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- Dizal presented compelling data from its robust portfolio of hematological oncology at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition held inSan Diego, California from December 9-12. The data showcased updated results of Dizal's ...

2023-12-12 18:00 2561

WuXi Biologics Named to 2023 Dow Jones Sustainability World Index

* Identified as a global sustainability leader by S&P Global * Committed to generating long-term value for all stakeholders SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), an...

2023-12-12 17:00 3310

Yum China to Report Fourth Quarter and Fiscal Year 2023 Financial Results

SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- Yum China Holdings, Inc. (NYSE: YUMC and HKEX: 9987, "Yum China" or the "Company") today announced that it will report its unaudited financial results for the fourth quarter and fiscal year endingDecember 31, 2023 at 4:30 p.m. U.S. Eastern Time on Tuesday, ...

2023-12-12 17:00 3684

MoonFox Data: JD.com Q3 profits exceeded expectations and the "low prices & supply chain" combo approach showed initial effectiveness

CHENGDU, China, Dec. 12, 2023 /PRNewswire/ -- About us: Aurora Mobile (NASDAQ: JG) established in 2011, is a leading customer engagement and marketing technology service provider inChina. Its business includes notification services, marketing growth, development tools, and data products. As its ...

2023-12-12 15:20 3368

MINISO Group Gives Updates on Increase Plan in Shareholding by Management

GUANGZHOU, China, Dec. 11, 2023 /PRNewswire/ -- MINISO Group Holding Limited (NYSE: MNSO; HKEX: 9896) ("MINISO", "MINISO Group" or the "Company"), a global value retailer offering a variety of trendy lifestyle products featuring IP design, today announced that Mr. Zhang Jingjing, the Company's Ch...

2023-12-12 12:15 2651

Live from ASH 2023 | Ascentage Pharma Presents the First Dataset of Bcl-2 inhibitor Lisaftoclax in Patients with AML, Demonstrating Favorable Efficacy and Safety

SUZHOU, China and ROCKVILLE, Md., Dec. 11, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released the results of lisaftoclax (A...

2023-12-12 09:41 3340

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

NEW YORK, Dec. 11, 2023 /PRNewswire/ -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the "Company") announced today that an aggregate of$50,000 has been deposited into the Company's trust account to further extend the period of time the Company has to consummate its business combination by an...

2023-12-12 05:30 2991

Lunit Advances to Stage 2 of Australia's National Breast Cancer Screening Project

* After a successful stage 1, Lunit INSIGHT MMG moves to prospective validation inAustralia's BreastScreen NSW Machine Reading Solution Project SEOUL, South Korea, Dec. 11, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therape...

2023-12-11 22:30 2833

Hollysys to be Acquired by Ascendent Capital Partners for US$26.50 in Cash Per Share

* Hollysys Board has unanimously approved Ascendent's all cash offer at 42% premium to the unaffected price as of23 August 2023 * Agreement marks culmination of formal sale process conducted by Special Committee of independent directors BEIJING, Dec. 11, 2023 /PRNewswire/ -- Hollysys Automati...

2023-12-11 22:10 4244

Zhongchao Inc. Collaborates with a Public Health Foundation to Support Sustainable and Effective Cancer Treatments

SHANGHAI, Dec. 11, 2023 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced that Shanghai Zhongxin Medical Technology Co., Ltd. ("Zhongxin"),...

2023-12-11 21:00 3344

WiMi Developed Holographic Complex Amplitude Computation and Update Technology

BEIJING, Dec. 11, 2023 /PRNewswire/ -- WiMi Hologram Cloud Inc. (NASDAQ: WIMI) ("WiMi" or the "Company"), a leading global Hologram Augmented Reality ("AR") Technology provider, today announced that it successfully developed a new technology----"Holographic Complex Amplitude Computation and Updat...

2023-12-11 21:00 2640

HanAll Biopharma's Partner, NurrOn Pharmaceuticals Incorporated Appoints Dr. Almira Chabi, MD, EGMP to Board of Directors

WOBURN, Mass., Dec. 11, 2023 /PRNewswire/ -- HanAll Biopharma's partner NurrOn Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of Parkinson's disease (PD) and other Nurr1-related human disorders, is pleased to...

2023-12-11 20:00 2641

Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC for Phase III Clinical Trial

SHANGHAI, Dec. 11, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its submission to the Center for Drug Evaluation (CDE) of the National Medical Products Administration for the "A Randomized, Open-label, Controlled, Mu...

2023-12-11 20:00 2023

2023 SABCS | Laekna Reports Afuresertib Phase Ib Breast Cancer Study Results

-     A multi-center phase Ib/III study in China and the United States led by ProfessorBinghe Xu, MD, PhD, Academician of the Chinese Academy of Engineering -     70% of the patients enrolled in phase Ib study were previously treated with CDK4/6 inhibitors  -     Demonstrated a confirmed objecti...

2023-12-11 18:55 2257

Qudian Inc. Reports Third Quarter 2023 Unaudited Financial Results

XIAMEN, China, Dec. 11, 2023 /PRNewswire/ -- Qudian Inc. ("Qudian" or "the Company" or "We") (NYSE: QD), a consumer-oriented technology company, today announced its unaudited financial results for the quarter endedSeptember 30, 2023. Third Quarter 2023 Financial Highlights: * Total revenues w...

2023-12-11 18:00 4084

Live from ASH 2023 | Ascentage Pharma Presents Updated Data from US Study of Olverembatinib, Further Validating Encouraging Efficacy in Patients Resistant to Ponatinib or Asciminib

SUZHOU, China, and ROCKVILLE, Md., Dec. 10, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data from a US study ...

2023-12-11 13:30 2161

Live from ASH 2023 | Ascentage Pharma Releases Encouraging Long-Term Data of Bcl-2 Inhibitor Lisaftoclax in R/R CLL, Including an ORR of 73.3%

SUZHOU, China and ROCKVILLE, Md., Dec. 10, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released the latest efficacy and safety...

2023-12-11 13:14 2114
1 ... 370371372373374375376 ... 763